Influenzavirus B Infections (Infectious Disease) - Drugs In Development, 2021

July 2021 | 212 pages | ID: I6B8407B671BEN
Global Markets Direct

Abstracts

Influenzavirus B Infections (Infectious Disease) - Drugs In Development, 2021

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Influenzavirus B Infections - Drugs In Development, 2021, provides an overview of the Influenzavirus B Infections (Infectious Disease) pipeline landscape.

Type B influenza is a subtype of the influenza virus that tends to occur sporadically. Symptoms include runny nose, sore throat, aching muscles, malaise, watery eyes, aching body, loss of appetite and weakness. Treatment includes antiviral, analgesics and antipyretics medications.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Influenzavirus B Infections - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Influenzavirus B Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Influenzavirus B Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Influenzavirus B Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 6, 10, 8, 9, 25 and 6 respectively. Similarly, the Universities portfolio in Phase III, Phase I, Preclinical and Discovery stages comprises 3, 1, 1 and 2 molecules, respectively.

Influenzavirus B Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Influenzavirus B Infections (Infectious Disease).
• The pipeline guide reviews pipeline therapeutics for Influenzavirus B Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Influenzavirus B Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Influenzavirus B Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Influenzavirus B Infections (Infectious Disease)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Influenzavirus B Infections (Infectious Disease).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Influenzavirus B Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Influenzavirus B Infections - Overview
Influenzavirus B Infections - Therapeutics Development
Influenzavirus B Infections - Therapeutics Assessment
Influenzavirus B Infections - Companies Involved in Therapeutics Development
Influenzavirus B Infections - Drug Profiles
Influenzavirus B Infections - Dormant Projects
Influenzavirus B Infections - Discontinued Products
Influenzavirus B Infections - Product Development Milestones
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Influenzavirus B Infections, 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Companies, 2021 (Contd..1)
Number of Products under Development by Companies, 2021 (Contd..2)
Number of Products under Development by Universities/Institutes, 2021
Products under Development by Companies, 2021
Products under Development by Companies, 2021 (Contd..1)
Products under Development by Companies, 2021 (Contd..2)
Products under Development by Companies, 2021 (Contd..3)
Products under Development by Universities/Institutes, 2021
Number of Products by Stage and Target, 2021
Number of Products by Stage and Mechanism of Action, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Influenzavirus B Infections - Pipeline by AbbVie Inc, 2021
Influenzavirus B Infections - Pipeline by Abhelix LLC, 2021
Influenzavirus B Infections - Pipeline by Adimmune Corp, 2021
Influenzavirus B Infections - Pipeline by Allergy Therapeutics Plc, 2021
Influenzavirus B Infections - Pipeline by Ansun Biopharma Inc, 2021
Influenzavirus B Infections - Pipeline by Aphios Corp, 2021
Influenzavirus B Infections - Pipeline by AstraZeneca Plc, 2021
Influenzavirus B Infections - Pipeline by AusBio Ltd, 2021
Influenzavirus B Infections - Pipeline by Biotron Ltd, 2021
Influenzavirus B Infections - Pipeline by BlueWillow Biologics Inc, 2021
Influenzavirus B Infections - Pipeline by Cidara Therapeutics Inc, 2021
Influenzavirus B Infections - Pipeline by Cocrystal Pharma Inc, 2021
Influenzavirus B Infections - Pipeline by ContraFect Corp, 2021
Influenzavirus B Infections - Pipeline by CSL Ltd, 2021
Influenzavirus B Infections - Pipeline by DAE HWA Pharmaceutical Co Ltd, 2021
Influenzavirus B Infections - Pipeline by e-Therapeutics Plc, 2021
Influenzavirus B Infections - Pipeline by Evotec SE, 2021
Influenzavirus B Infections - Pipeline by Evrys Bio, 2021
Influenzavirus B Infections - Pipeline by FUJIFILM Toyama Chemical Co Ltd, 2021
Influenzavirus B Infections - Pipeline by Ginkgo Tree Pharmaceutical (Suzhou) Co Ltd, 2021
Influenzavirus B Infections - Pipeline by Hangzhou Zenshine Pharmaceuticals Co Ltd, 2021
Influenzavirus B Infections - Pipeline by Imutex Ltd, 2021
Influenzavirus B Infections - Pipeline by Inovio Pharmaceuticals Inc, 2021
Influenzavirus B Infections - Pipeline by Institute of Virology Vaccines and Sera Torlak, 2021
Influenzavirus B Infections - Pipeline by iQur Ltd, 2021
Influenzavirus B Infections - Pipeline by Jiangsu Ab&b Biotechnology Co Ltd, 2021
Influenzavirus B Infections - Pipeline by Jiangsu Carephar Pharmaceutical Co Ltd, 2021
Influenzavirus B Infections - Pipeline by Johnson & Johnson, 2021
Influenzavirus B Infections - Pipeline by Kentucky BioProcessing Inc, 2021
Influenzavirus B Infections - Pipeline by Liaoning Cheng Da Biotechnology Co Ltd, 2021
Influenzavirus B Infections - Pipeline by Medicago Inc, 2021
Influenzavirus B Infections - Pipeline by Moderna Inc, 2021
Influenzavirus B Infections - Pipeline by Novavax Inc, 2021
Influenzavirus B Infections - Pipeline by Osivax SAS, 2021
Influenzavirus B Infections - Pipeline by Park Active Molecules, 2021
Influenzavirus B Infections - Pipeline by Pentavalent Bio Sciences Pvt Ltd, 2021
Influenzavirus B Infections - Pipeline by Revelation Biosciences Inc, 2021
Influenzavirus B Infections - Pipeline by Romark Laboratories LC, 2021
Influenzavirus B Infections - Pipeline by SAB Biotherapeutics Inc, 2021
Influenzavirus B Infections - Pipeline by Sanofi, 2021
Influenzavirus B Infections - Pipeline by Sciogen Inc, 2021
Influenzavirus B Infections - Pipeline by Seqirus Ltd, 2021
Influenzavirus B Infections - Pipeline by Serum Institute of India Pvt Ltd, 2021
Influenzavirus B Infections - Pipeline by Shanghai Institute of Biological Products Co Ltd, 2021
Influenzavirus B Infections - Pipeline by Shionogi & Co Ltd, 2021
Influenzavirus B Infections - Pipeline by Symvivo Inc, 2021
Influenzavirus B Infections - Pipeline by TaiGen Biotechnology Co Ltd, 2021
Influenzavirus B Infections - Pipeline by Therapeutic Systems Research Laboratories Inc, 2021
Influenzavirus B Infections - Pipeline by Trellis Bioscience Inc, 2021
Influenzavirus B Infections - Pipeline by Tria Bioscience Corp, 2021
Influenzavirus B Infections - Pipeline by UMN Pharma Inc, 2021
Influenzavirus B Infections - Pipeline by Vacthera BioTech GmbH, 2021
Influenzavirus B Infections - Pipeline by Ventaleon GmbH, 2021
Influenzavirus B Infections - Pipeline by Viramatix Sdn Bhd, 2021
Influenzavirus B Infections - Pipeline by Walvax Biotechnology Co Ltd, 2021
Influenzavirus B Infections - Pipeline by Wuhan Institute of Biological Products Co Ltd, 2021
Influenzavirus B Infections - Dormant Projects, 2021
Influenzavirus B Infections - Dormant Projects, 2021 (Contd..1)
Influenzavirus B Infections - Discontinued Products, 2021

List Of Figures

LIST OF FIGURES

Number of Products under Development for Influenzavirus B Infections, 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Number of Products by Top 10 Targets, 2021
Number of Products by Stage and Top 10 Targets, 2021
Number of Products by Top 10 Mechanism of Actions, 2021
Number of Products by Stage and Top 10 Mechanism of Actions, 2021
Number of Products by Top 10 Routes of Administration, 2021
Number of Products by Stage and Top 10 Routes of Administration, 2021
Number of Products by Top 10 Molecule Types, 2021
Number of Products by Stage and Top 10 Molecule Types, 2021